Insulet Cash Flow Statement
NASDAQ: PODDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Insulet free cash flow
In fiscal 2025, Insulet generated $569.3 million of operating cash flow and spent $191.6 million on capital expenditures. That left free cash flow of $377.7 million, a free-cash-flow margin of 13.9% of revenue. Free cash flow was up 23.7% from the prior year's $305.3 million.
Insulet returned $59.6 million to shareholders through share repurchases, equal to 16% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Insulet cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M | 6.80M | 11.60M | 3.30M | -26.80M | -28.88M |
| Net Income growth (YoY) | -40.93% | +102.76% | +4384.78% | -72.62% | +147.06% | -41.38% | +251.52% | — | — | — |
| Depreciation & Amortization | 90.40M | 80.80M | 72.80M | 63.20M | 57.40M | 55.40M | 27.90M | 15.60M | 13.90M | 13.83M |
| Stock-Based Compensation | 62.70M | 69.30M | 48.40M | 40.90M | 34.40M | 35.90M | 28.70M | 37.50M | 31.90M | 23.62M |
| Change in Working Capital | -43.10M | -52.10M | -206.10M | -101.20M | -262.20M | -91.20M | -32.30M | -75.60M | -25.66M | -14.22M |
| Operating Cash Flow | 569.30M | 430.20M | 145.70M | 119.00M | -68.10M | 84.00M | 98.40M | 35.90M | 41.30M | 15.91M |
| Capital Expenditures | -191.60M | -124.90M | -75.60M | -122.90M | -111.90M | -129.00M | -163.70M | -157.40M | -73.80M | -22.11M |
| Investing Cash Flow | -222.70M | -146.20M | -119.40M | -191.10M | -82.70M | 14.00M | -73.60M | -184.50M | -210.80M | -178.01M |
| Share Repurchases | -59.60M | 0 | 0 | — | — | — | — | — | — | — |
| Debt Issued | 440.70M | 0 | 0 | — | — | — | 780.20M | 0 | 391.60M | 333.73M |
| Financing Cash Flow | -595.30M | -28.00M | -13.60M | -40.30M | 40.70M | 605.50M | 73.50M | -8.70M | 304.50M | 176.57M |
| Net Change in Cash | -237.30M | 249.20M | 14.40M | -116.70M | -115.60M | 708.30M | 99.80M | -158.70M | 135.40M | 14.50M |
| Free Cash Flow | 377.70M | 305.30M | 70.10M | -3.90M | -180.00M | -45.00M | -65.30M | -121.50M | -32.50M | -6.20M |
This table shows 10 annual periods of Insulet's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PODD's reporting calendar. What is a cash flow statement?